Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2019 Symposium /
CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer

23rd - 24th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 557

Dr Hikmat Abdel-Razeq - King Hussein Cancer Center, Amman, Jordan

Dr Hikmat Abdel-Razeq speaks to ecancer at the WIN 2019 Symposium in Paris about the use of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, metastatic breast cancer.

Dr Abdel-Razaq explains the issue of resistance when treated with conventional therapies such as aromatase inhibitors, however, the addition of CDK4/6 inhibitors seems to modulate the resistance, increased progression-free survival and provided an overall survival benefit - as shown in the MONALEESA-7 trial.

He also discusses the cost-effectiveness of these drugs and the potential use of these in other disease areas, such as non-small cell lung cancer (NSCLC).


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation